BriaCell Therapeutics Corp. (TSX:BCT)
Canada · Delayed Price · Currency is CAD | Market Cap | 35.65M +49.4% |
| Revenue (ttm) | n/a |
| Net Income | -40.23M |
| EPS | -47.35 |
| Shares Out | 6.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,166 |
| Average Volume | 40,991 |
| Open | 5.71 |
| Previous Close | 5.74 |
| Day's Range | 5.50 - 5.71 |
| 52-Week Range | 5.50 - 135.00 |
| Beta | 2.03 |
| RSI | 37.54 |
| Earnings Date | Mar 13, 2026 |
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co... [Read more]
News
BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment
BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-sta...
BriaCell (BCTX) Reports Promising Phase 2 Survival Data
BriaCell (BCTX) Reports Promising Phase 2 Survival Data
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria-...
Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?
BriaCell Therapeutics Corp's (NYSE: BCTX) short interest as a percent of float has risen 174.82% since its last report. According to exchange reported data, there are now 281 thousand shares sold sho...
Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch
(RTTNews) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes, rare diseases, bi...
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
What's Going On With BriaCell Therapeutics Stock Wednesday?
BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock plunged on Wednesday after rallying on Tuesday on positive data from a breast cancer trial. This small biotechnology company, focused on cancer, has a...
BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering
(RTTNews) - BriaCell Therapeutics Corp. (BCTX, BCTXL), a clinical-stage biotechnology company, on Wednesday announced the pricing of a public offering of 5.367 million units at $5.59 per unit, for gro...
BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%
BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%
BriaCell Therapeutics (BCTX) Launches $30M Public Offering
BriaCell Therapeutics (BCTX) Launches $30M Public Offering
BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit
BriaCell Therapeutics (BCTX) priced a $30M offering at $5.59/unit with warrants; shares fell 9.7% after hours.
BriaCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study
(RTTNews) - BriaCell Therapeutics Corp. (BCTX) shares were trading at $10.61, up 39.06% or $2.98 higher, following news of a sustained complete resolution of a lung metastasis in a metastatic breast c...
BriaCell Surge Above 50%; What's The Buzz?
(RTTNews) - BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, on Tuesday reported durable and sustained complete resolution of a lung metastasis in a patient with metastatic ...
BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial
BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biot...
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium
BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer
BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium
BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...